Osteogenic effects of resveratrol in vitro: Potential for the prevention and treatment of osteoporosis

Annals of the New York Academy of Sciences

Volumn 1290, Issue 1, 2013, Pages 59-66

  Mobasheri, Ali ^a,b   Shakibaei, Mehdi ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Menopause; Osteogenesis; Osteoporosis; Phytoestrogen; Resveratrol

Indexed keywords

CURCUMIN; ESTROGEN; PHYTOESTROGEN; RESVERATROL; SIRTUIN;

ARTHRITIS; ARTICLE; BONE CELL; BONE DEVELOPMENT; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; DRUG POTENTIATION; ESTROGEN THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METABOLIC BONE DISEASE; NONHUMAN; NUTRITIONAL SUPPORT; OSTEOPOROSIS; POSTMENOPAUSE;

EID: 84880338607     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12145     Document Type: Article

References (42)

1. Ascenzi, M.G. & A.K. Roe. 2012. The osteon: the micromechanical unit of compact bone. Front Biosci. 17: 1551-1581.
2. Del Fattore, A., A. Teti & N. Rucci. 2012. Bone cells and the mechanisms of bone remodelling. Front Biosci. 4: 2302-2321.
3. Rosen, C.J. 2000. Pathogenesis of osteoporosis. Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 14: 181-193.
4. Burr, D.B. & M.A. Gallant. 2012. Bone remodelling in osteoarthritis. Nat. Rev. Rheumatol. 8: 665-673.
5. Rizzoli, R. 2007. Osteoporosis: non-hormonal treatment. Climacteric 10: 74-78.
6. Spector, T.D. 2003. Bisphosphonates: potential therapeutic agents for disease modification in osteoarthritis. Aging Clin. Exp. Res. 15: 413-418.
7. Weitzmann, M.N. & R. Pacifici. 2006. Estrogen deficiency and bone loss: an inflammatory tale. J. Clin. Invest. 116: 1186-1194.
8. Felson, D.T., Y. Zhang, M.T. Hannan, et al. 1993. The effect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med. 329: 1141-1146.
9. Popat, V.B., K.A. Calis, V.H. Vanderhoof, et al. 2009. Bone mineral density in estrogen-deficient young women. J. Clin. Endocrinol. Metab. 94: 2277-2283.
10. Martin-Millan, M. & S. Castaneda. 2013. Estrogens, osteoarthritis and inflammation. Joint Bone Spine. doi: 10.1016/j.jbspin.2012.11.008.
11. Khosla, S., L.J. Melton, 3rd, E.J. Atkinson, et al. 1998. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J. Clin. Endocrinol. Metab. 83: 2266-2274.
12. Wassertheil-Smoller, S. et al. 2004. Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI). Arch. Intern. Med. 164: 289-298.
13. Schilling, T. et al. 2012. Effects of phytoestrogens and other plant-derived compounds on mesenchymal stem cells, bone maintenance and regeneration. J. Steroid Biochem. Mol. Biol. doi: 10.1016/j.jsbmb.2012.12.006.
14. Patisaul, H.B. & W. Jefferson. 2010. The pros and cons of phytoestrogens. Front Neuroendocrinol. 31: 400-419.
15. Chiang, S.S. & T.M. Pan. 2013. Beneficial effects of phytoestrogens and their metabolites produced by intestinal microflora on bone health. Appl. Microbiol. Biotechnol. 97: 1489-1500.
16. Csiszar, A. 2011. Anti-inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease. Ann. N.Y. Acad. Sci. 1215: 117-122.
17. Mizutani, K. et al. 1998. Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 253: 859-863.
18. Turner, R.T. et al. 1999. Is resveratrol an estrogen agonist in growing rats? Endocrinology 140: 50-54.
19. Liu, Z.P. et al. 2005. Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model. J. Med. Food 8: 14-19.
20. Shakibaei, M., C. Buhrmann & A. Mobasheri. 2011. Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells. J. Biol. Chem. 286: 11492-11505.
21. Shakibaei, M. et al. 2012. Resveratrol mediated modulation of Sirt-1/Runx2 promotes osteogenic differentiation of mesenchymal stem cells: potential role of Runx2 deacetylation. PLoS One 7: e35712.
22. Boyce, B.F. & L. Xing. 2007. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res. Ther. 9: S1.
23. Mobasheri, A. et al. 2012. Scientific evidence and rationale for the development of curcumin and resveratrol as nutraceutricals for joint health. Int. J. Mol. Sci. 13: 4202-4232.
24. Csaki, C. et al. 2008. Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem. Pharmacol. 75: 677-687.
25. Csaki, C., A. Mobasheri & M. Shakibaei. 2009. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res. Ther. 11: R165.
26. Shakibaei, M. et al. 2008. Resveratrol suppresses interleukin-1beta-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem. Pharmacol. 76: 1426-1439.
27. Shakibaei, M. et al. 2007. Resveratrol inhibits IL-1 beta-induced stimulation of caspase-3 and cleavage of PARP in human articular chondrocytes in vitro. Ann. N.Y. Acad. Sci. 1095: 554-563.
28. Tseng, P.C. et al. 2011. Resveratrol promotes osteogenesis of human mesenchymal stem cells by upregulating RUNX2 gene expression via the SIRT1/FOXO3A axis. J. Bone Miner. Res. 26: 2552-2563.
29. Dai, Z. et al. 2007. Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine 14: 806-814.
30. Buhrmann, C. et al. 2010. Curcumin mediated suppression of nuclear factor-kappaB promotes chondrogenic differentiation of mesenchymal stem cells in a high-density co-culture microenvironment. Arthritis Res. Ther. 12: R127.
31. Kim, J. et al. 2010. Mitochondrial DNA damage is involved in apoptosis caused by pro-inflammatory cytokines in human OA chondrocytes. Osteoarthritis Cartilage 18: 424-432.
32. Morris, B.J. 2013. Seven sirtuins for seven deadly diseases of aging. Free Radic. Biol. Med. 56: 133-171.
33. Dave, M. et al. 2008. The antioxidant resveratrol protects against chondrocyte apoptosis via effects on mitochondrial polarization and ATP production. Arthritis Rheum. 58: 2786-2797.
34. Mobasheri, A. 2012. Intersection of inflammation and herbal medicine in the treatment of osteoarthritis. Curr. Rheumatol. Rep. 14: 604-616.
35. Sinha, K., G. Chaudhary & Y.K. Gupta. 2002. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci. 71: 655-665.
36. Lopez-Velez, M., F. Martinez-Martinez & C. Del Valle-Ribes. 2003. The study of phenolic compounds as natural antioxidants in wine. Crit. Rev. Food Sci. Nutr. 43: 233-244.
37. Shen, C.L. et al. 2012. Fruits and dietary phytochemicals in bone protection. Nutr. Res. 32: 897-910.
38. Sacco, S.M., M.N. Horcajada & E. Offord. 2013. Phytonutrients for bone health during ageing. Br. J. Clin. Pharmacol. 75: 697-707.
39. Lai, C.Y. et al. 2011. Preventing bone loss and weight gain with combinations of vitamin D and phytochemicals. J. Med. Food 14: 1352-1362.
40. Almeida, L. et al. 2009. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 53: S7-S15.
41. Kupisiewicz, K. et al. 2010. Potential of resveratrol analogues as antagonists of osteoclasts and promoters of osteoblasts. Calcif. Tissue Int. 87: 437-449.
42. Henrotin, Y. et al. 2013. Physiological effects of oral glucosamine on joint health: current status and consensus on future research priorities. BMC Res. Notes 6: 115.